Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.12 USD

96.12
370,120

+0.08 (0.08%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Wright Medical (WMGI) Stock

Strong international footprint, solid prospects in the global orthopedic space and an enhanced product pipeline bode well for Wright Medical (WMGI). However, adverse forex mars prospects.

Illumina (ILMN) Gains on Product Pipeline, Global Footprint

Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).

Medtronic's MiniMed 670G Shows Favorable Outcome in Europe

Medtronic's (MDT) MiniMed 670G system boasts a special feature of SmartGuard Auto Mode that improves Time in Range.

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind

Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.

PRA Health Simplifies Treatment Decisions With Metys Launch

PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.

Here's Why You Should Retain Pacific Biosciences For Now

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.

3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)

Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.

Intersect ENT Rides on Innovation Amid Pricing Concerns

The SINUVA business line of Intersect ENT (XENT) makes a quick and remarkable progress with market access and field force balance.

HMS Holdings Acquires VitreosHealth, Boosts PHM Solution Set

HMS Holdings (HMSY) can leverage VitreosHealth's prescriptive health insights that will enhance its growing and lucrative PHM suite.

Here's Why You Should Retain OPKO Health (OPK) Stock For Now

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and solid R&D focus. However, operating losses remain a woe.

Medtronic Collaborates With Novo Nordisk for Diabetes Care

This collaboration is expected to boost Medtronic's (MDT) diabetes management portfolio.

Sumit Singh headshot

Add These 5 Stocks With Impressive Interest Coverage Ratio

Interest coverage ratio is used to determine how effectively a company can pay the interest charged on its debt.

DVA vs. AMED: Which Stock Should Value Investors Buy Now?

DVA vs. AMED: Which Stock Is the Better Value Option?

BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal

This collaboration is expected to bolster BioSig's (BSGM) commitment toward offering higher quality patient care by introducing innovative technological solutions to medicine.

Here's Why You Should Hold on to Ecolab (ECL) Stock Now

Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.

Bruker (BRKR) Introduces the nanoIR3-s Broadband System

The launch of the FTIR spectroscopy system complements Bruker's (BRKR) target to boost its portfolio of nanoIR products.

Integra Buys Rebound Therapeutics to Boost Neurosurgery Line

Integra (IART) believes, Rebound's MIS technological arm will widen its neurosurgical pipeline within Codman Specialty Surgical space.

Medtronic's (MDT) MiniMed 670G Gains German Reimbursement

Medtronic's (MDT) MiniMed 670G is witnessing a solid uptake in the United States ever since its launch last year.

Medtronic's (MDT) IN.PACT AV Access Study Results Bode Well

The results of the study will prove to be a major stride for Medtronic (MDT) to treat patient suffering from renal diseases.

Here's Why You Should Invest in Intuitive Surgical (ISRG) Now

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base.

Masimo (MASI) Boosts O3 Platform With Three New Indices

Masimo (MASI) announced the development of three additional indices for O3 Regional Oximetry, thereby improving the O3 platform.

Here's Why You Should Retain NextGen Healthcare Stock Now

NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

Here's Why You Should Invest in Amedisys (AMED) Right Now

Amedisys (AMED) is currently enjoying investors' confidence, thanks to solid prospects.

Here's Why You Should Invest in Integer Holdings (ITGR) Now

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.